Save time and get answers to complex questions with AI chat
When is tenofovir alafenamide patent expiring?Motegrity ingredients?Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?Novartis patent term dabrafenib?Dabrafenib and trametinib price?
See the DrugPatentWatch profile for Alprolix
Alprolix (albutrepenonacog alfa) was approved by the U.S. Food and Drug Administration (FDA) on May 2, 2017. [1]
That approval date is the initial FDA approval date for Alprolix as a clotting-factor replacement therapy for hemophilia B. [1]
You can confirm the FDA approval date via DrugPatentWatch.com’s drug profile for Alprolix. [1] Sources: [1] https://www.drugpatentwatch.com/p/alprolix/
Other Questions About Alprolix :